<DOC>
	<DOCNO>NCT00897910</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood bone marrow patient cancer laboratory may help doctor learn T cell plan good treatment multiple myeloma . PURPOSE : This research study look T cell blood bone marrow sample patient multiple myeloma .</brief_summary>
	<brief_title>Studying T Cells Blood Bone Marrow Samples From Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility expand myeloma-specific T cell use autologous ex vivo expand B cell load myeloma antigen antigen-presenting cell ( B-APCs ) peripheral blood bone marrow sample patient multiple myeloma . Secondary - To examine feasibility select expand myeloma-specific T cell ex vivo use interferon γ release CD3/CD28 stimulation . OUTLINE : Peripheral blood bone marrow sample collect periodically laboratory study . Samples analyze assess feasibility expand autologous B cell ex vivo use CD40L IL-4 ; antigen-presenting phenotype autologous B-cell antigen-presenting cell ( B-APCs ) use flow cytometry ; antigen-presenting function B-APCs use ELISPOT chromium-release assay . Myeloma-specific interferon γ secrete T cell isolate select use Miltenyi bead . The select myeloma-specific T cell expand ex vivo use anti CD3/CD28 bead .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>